New hope for kids with sickle cell pain
NCT ID NCT03474965
Summary
This study tested the safety and correct dosing of a drug called crizanlizumab in children aged 2 to 18 with sickle cell disease. The goal was to see if the drug, given as a monthly infusion, could safely reduce the frequency of painful vaso-occlusive crises. Researchers studied 117 children over two years to find the right dose for different age groups.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE (SCD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Childrens Healthcare of Atlanta
Atlanta, Georgia, 30342, United States
-
Childrens Hosp Boston Dept of Hematology
Boston, Massachusetts, 02115, United States
-
Childrens Hospital Of Philadelphia
Philadelphia, Pennsylvania, 19104-4399, United States
-
Childrens Hospital at Montefiore
The Bronx, New York, 10467, United States
-
Childrens National Hospital
Washington D.C., District of Columbia, 20010, United States
-
Cook Childrens Medical Center
Fort Worth, Texas, 76104, United States
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
-
East Carolina University
Greenville, North Carolina, 27834, United States
-
Joe DiMaggio Childrens Hospital
Hollywood, Florida, 33021, United States
-
Medical Uni of South Carolina
Charleston, South Carolina, 29425, United States
-
Novartis Investigative Site
Brussels, 1000, Belgium
-
Novartis Investigative Site
Laken, 1020, Belgium
-
Novartis Investigative Site
Liège, 4000, Belgium
-
Novartis Investigative Site
Salvador, Estado de Bahia, 41253-190, Brazil
-
Novartis Investigative Site
Ribeirão Preto, São Paulo, 14048-900, Brazil
-
Novartis Investigative Site
São Paulo, São Paulo, 01232-010, Brazil
-
Novartis Investigative Site
Montreal, Quebec, H3T 1C5, Canada
-
Novartis Investigative Site
Cali, Valle del Cauca Department, 760012, Colombia
-
Novartis Investigative Site
Montería, 230004, Colombia
-
Novartis Investigative Site
Paris, 75015, France
-
Novartis Investigative Site
Heidelberg, 69120, Germany
-
Novartis Investigative Site
Nagpur, Maharashtra, 440009, India
-
Novartis Investigative Site
Padua, PD, 35128, Italy
-
Novartis Investigative Site
Orbassano, TO, 10043, Italy
-
Novartis Investigative Site
Beirut, 1107 2020, Lebanon
-
Novartis Investigative Site
Tripoli, 1434, Lebanon
-
Novartis Investigative Site
Muscat, 123, Oman
-
Novartis Investigative Site
Palma de Mallorca, Balearic Islands, 07120, Spain
-
Novartis Investigative Site
Barcelona, Catalonia, 08035, Spain
-
Novartis Investigative Site
Madrid, 28009, Spain
-
Novartis Investigative Site
Adana, 01330, Turkey (Türkiye)
-
Novartis Investigative Site
Mersin, 33110, Turkey (Türkiye)
-
Novartis Investigative Site
London, SE1 7EH, United Kingdom
-
University Of Alabama
Birmingham, Alabama, 35233, United States
-
University of Florida
Gainesville, Florida, 32610, United States
Conditions
Explore the condition pages connected to this study.